Blagden S - Search Results

1

Cerebral sinus thrombosis and leptomeningeal carcinomatosis in a patient with ovarian cancer.

Li HK, Harding V, Williamson R, Blagden S, Gabra H, Agarwal R. Li HK, et al. Among authors: blagden s. J Clin Oncol. 2012 Jan 10;30(2):e19-20. doi: 10.1200/JCO.2011.38.1426. Epub 2011 Dec 12. J Clin Oncol. 2012. PMID: 22162572 No abstract available.

2

Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors.

Luke JJ, Fakih M, Schneider C, Chiorean EG, Bendell J, Kristeleit R, Kurzrock R, Blagden SP, Brana I, Goff LW, O'Hayer K, Geschwindt R, Smith M, Zhou F, Naing A. Luke JJ, et al. Among authors: blagden sp. Br J Cancer. 2023 Jun;128(12):2227-2235. doi: 10.1038/s41416-023-02267-1. Epub 2023 Apr 22. Br J Cancer. 2023. PMID: 37087488 Free PMC article. Clinical Trial.

3

First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors.

Davis EJ, Martin-Liberal J, Kristeleit R, Cho DC, Blagden SP, Berthold D, Cardin DB, Vieito M, Miller RE, Hari Dass P, Orcurto A, Spencer K, Janik JE, Clark J, Condamine T, Pulini J, Chen X, Mehnert JM. Davis EJ, et al. J Immunother Cancer. 2022 Oct;10(10):e004235. doi: 10.1136/jitc-2021-004235. J Immunother Cancer. 2022. PMID: 36316061 Free PMC article. Clinical Trial.

4

A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer.

Kristeleit R, Plummer R, Jones R, Carter L, Blagden S, Sarker D, Arkenau T, Evans TRJ, Danson S, Symeonides SN, Veal GJ, Klencke BJ, Kowalski MM, Banerji U. Kristeleit R, et al. Among authors: blagden s. Br J Cancer. 2023 Jul;129(1):38-45. doi: 10.1038/s41416-023-02279-x. Epub 2023 Apr 29. Br J Cancer. 2023. PMID: 37120671 Free PMC article. Clinical Trial.

5

Future directions in the management of epithelial ovarian cancer.

Blagden S, Gabra H. Blagden S, et al. Future Oncol. 2008 Jun;4(3):403-11. doi: 10.2217/14796694.4.3.403. Future Oncol. 2008. PMID: 18518765 Review.

6

Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer.

Sharma R, Graham J, Mitchell H, Brooks A, Blagden S, Gabra H. Sharma R, et al. Among authors: blagden s. Br J Cancer. 2009 Mar 10;100(5):707-12. doi: 10.1038/sj.bjc.6604914. Epub 2009 Feb 17. Br J Cancer. 2009. PMID: 19223898 Free PMC article.

7

Promising molecular targets in ovarian cancer.

Blagden S, Gabra H. Blagden S, et al. Curr Opin Oncol. 2009 Sep;21(5):412-9. doi: 10.1097/CCO.0b013e32832eab1f. Curr Opin Oncol. 2009. PMID: 19553815 Review.

8

The RNA binding protein Larp1 regulates cell division, apoptosis and cell migration.

Burrows C, Abd Latip N, Lam SJ, Carpenter L, Sawicka K, Tzolovsky G, Gabra H, Bushell M, Glover DM, Willis AE, Blagden SP. Burrows C, et al. Nucleic Acids Res. 2010 Sep;38(16):5542-53. doi: 10.1093/nar/gkq294. Epub 2010 Apr 29. Nucleic Acids Res. 2010. PMID: 20430826 Free PMC article.

9

Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/refractory epithelial ovarian cancer.

Sharma R, Graham J, Blagden S, Gabra H. Sharma R, et al. Among authors: blagden s. BMC Cancer. 2011 Jul 11;11:289. doi: 10.1186/1471-2407-11-289. BMC Cancer. 2011. PMID: 21745358 Free PMC article. Clinical Trial.

10

A study of symptoms described by ovarian cancer survivors.

Stavraka C, Ford A, Ghaem-Maghami S, Crook T, Agarwal R, Gabra H, Blagden S. Stavraka C, et al. Among authors: blagden s. Gynecol Oncol. 2012 Apr;125(1):59-64. doi: 10.1016/j.ygyno.2011.12.421. Epub 2011 Dec 9. Gynecol Oncol. 2012. PMID: 22155797

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

103 results

Search Page